Biotech firm Moderna recently announced that it would never enforce the patent on its COVID-19 vaccine in 92 countries currently receiving the shots through a global program. It’s the first major pharmaceutical company to announce such a move, which critics say came later than it should have and which opens the door to wide-scale global production. Under CEO Stéphane Bancel, Moderna is also developing mRNA vaccines targeting 15 pathogens that are more common in the developing world, as well as longtime public-health threats such as influenza and RSV.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
More Must-Reads From TIME
- What a Photographer Saw in the West Bank
- Accenture’s Chief AI Officer on Why This Is a Defining Moment
- Inside COP28's Big 'Experiment'
- U.S. Doctors Can't Be Silent About Gaza: Column
- The Movie Wives Would Like a Word
- The 100 Must-Read Books of 2023
- The Top 100 Photos of 2023
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
